Latham & Watkins Advises on Alamar Biosciences’ Upsized US$191.3 Million Initial Public Offering

Alamar Biosciences, Inc. (Alamar), a leader in precision proteomics dedicated to advancing the early detection of disease, has announced the pricing of its upsized initial public offering of 11,250,000 shares of its common stock at a public offering price of US$17 per share. In addition, Alamar has granted the underwriters a 30‑day option to purchase up to an additional 1,687,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Select Market on April 17, 2026, under the ticker symbol ALMR. The gross proceeds from the offering are expected to be approximately US$191.3 million, without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on April 20, 2026, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represented the underwriters in the offering with a Capital Markets team led by New York partner Nathan Ajiashvili and Orange County/Bay Area partner Ross McAloon, with associates Raul Gonzalez Cassarubias, Lexi Zintel, and Skyler Ligon.